Clinical trials: COVID19 Patients
Long COVID
Tele-exercise Training Program for Long COVID
Patients with long coronavirus disease (COVID-19) experience multisystem symptoms and reduced quality of life (QOL). Proactive interventions are needed to enhance health outcomes.To investigate the effects of a 12-week…
- Trial name
- NCT07553897
- Testing
- Telehealth exercise training program, Education and self-exercise
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Tri-Service General Hospital (TSGH)
COVID-19 Acute Respiratory Distress Syndrome
Macintosh Versus Macgrath for Laryngoscopy in COVID 19 Hypoxemic ICU Patients
In this comparative prospective study, we aim to compare the classic Macintosh laryngoscope and the Mac Grath videolaryncoscope in ICU covid 19 patients recruiting intubation and invasive mechanical ventilation.
- Trial name
- NCT04956913
- Testing
- Mac Grath, Macintosh
- Volunteers
- 80 people
- Sponsor
- Mongi Slim Hospital
SARS-CoV 2, Hospitalisation-Associated Infection
Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients
The inflammation is central in COVID-19 infections. Our aim is to evaluate the clinical value of measuring inflammation by using serum protein electrophoresis (SPE).
- Trial name
- COVELEC (NCT04414059)
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Elsan
COVID, Acute Coronary Syndrome
Cardiovascular Complications and COVID-19 (CovCardioVasc-Study)
Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death).
- Conditions
- COVID, Acute Coronary Syndrome, Myocardial Infarction, Myocarditis
- Trial name
- CovCardioVasc (NCT04335162)
- Where
- 8 sites in France
- Volunteers
- 198 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Covid19, SARS-Associated Coronavirus
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild…
- Trial name
- NCT04727424
- Testing
- Spirulin Platensis, Budesonide Powder, Fluoxetine 20 MG
- Where
- 12 sites in Brazil
- Volunteers
- 7,819 people
- Sponsor
- Cardresearch
Post ICU Rehabilitation
Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era
In this clinical study, the investigators will compare vital parameters measurements obtained using continuous data from reference monitors and continuous wireless MultiSense® monitoring patch in 60 post-ICU (Intensive Care Unit)…
- Trial name
- MONIREA (NCT04661423)
- Testing
- Remote Automated Monitoring System
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- IHU Strasbourg
COVID-19 Pneumonia
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
- Trial name
- NCT04561180
- Testing
- EG-009A, Standard of Care, Dexamethasone
- Sponsor
- Evergreen Therapeutics, Inc.
covid19
Predictive Factors COVID-19 Patients
This is a monocentric retro-prospective observational study that will be conducted on all COVID19 positive patients hospitalized at the S. Gerardo Hospital in Monza.
- Trial name
- MI-COVID (NCT04427345)
- Testing
- Predictive factors for clinical response in patients with COVID-19.
- Where
- Italy
- Sponsor
- University of Milano Bicocca
Covid19
Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal…
- Trial name
- NCT04570501
- Testing
- Angiotensin-(1-7)
- Where
- United States
- Sponsor
- Stanford University
Emergencies
Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea
This research aims to improve our knowledge of the epidemiology of patients consulting in the COvid-19 Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID-19 affects France and impacts its health system.
- Trial name
- EPRICOD (NCT04422587)
- Testing
- RECOP unit patient
- Where
- France
- Volunteers
- 1,860 people
- Sponsor
- University Hospital, Toulouse
COVID-19 Vaccines, Autoimmune Diseases
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
According to the comprehensive evaluation, the completion of vaccination and the prevention and treatment strategy of integrated traditional Chinese and western medicine have obvious advantages in improving the symptoms of…
- Trial name
- NCT05831826
- Testing
- the inactivated COVID-19 vaccines
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Chinese Medical University
COVID 19, Coronavirus
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients.
- Conditions
- COVID 19, Coronavirus, Diabetes Mellitus, Type 2, Diabetes Mellitus
- Trial name
- NCT04371978
- Testing
- Linagliptin 5 MG
- Where
- 3 sites in Israel
- Volunteers
- 64 people
- Sponsor
- Rabin Medical Center
Covid19
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19
In a 2x2 factorial design randomized controlled trial, the investigators aim to elaborate the safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients with COVID-19.
- Trial name
- INSPIRATION (NCT04486508)
- Testing
- intermediate dose Enoxaparin/ unfractionated heparin, standard prophylactic dose Enoxaparin/ unfractionated heparin, Atorvastatin 20mg
- Where
- Iran
- Volunteers
- 600 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
COVID-19
Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients.
- Trial name
- NCT05675748
- Testing
- Azvudine
- Volunteers
- 400 people
- Sponsor
- Shanghai Henlius Biotech
Patients With Cancers, COVID-19
Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020. Patients with cancers may be at higher risk than those without cancer for coronavirus disease 2019 (COVID-19).
- Conditions
- Patients With Cancers, COVID-19, Vaccine
- Trial name
- NCT05018078
- Testing
- Coronavirus vaccine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing 302 Hospital
Early CPAP Ventilation in COVID-19 Patients
Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.
This cohort study aims at prospectively collecting detailed clinical information on patients positive to or suspected of COVID-19 visiting Italian emergency departments (EDs). The objectives of the study are: 1.
- Trial name
- EC-COVID-PCS (NCT04323878)
- Where
- Italy
- Volunteers
- 6,000 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Covid19
ACTIV-3: Therapeutics for Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- TICO (NCT04501978)
- Testing
- LY3819253, Remdesivir, VIR-7831
- Where
- 135 sites in United States, Denmark and 8 more
- Volunteers
- 2,753 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Favipiravir
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study.
- Conditions
- COVID-19, Favipiravir, Kaletra, Hydroxychloroquine
- Trial name
- NCT04376814
- Testing
- Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Baqiyatallah Medical Sciences University
COVID-19
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
This study evaluates treatment with Favipiravir combined with supportive care for adult patients with COVID-19-moderate type.
- Trial name
- NCT04336904
- Testing
- Favipiravir
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Giuliano Rizzardini
COVID-19
Neuromodulation in COVID-19 Patients
This clinical study is aimed at investigating the effects of transcranial direct current stimulation (tDCS) on COVID-19 patients not admitted to the intensive care unit.
- Trial name
- NCT04808284
- Testing
- Transcranial direct-current stimulation
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- D'Or Institute for Research and Education
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.